The investigation follows allegations that Ensign may have provided materially misleading business information to the public. Hunterbrook’s findings, which surfaced after a five-month inquiry, suggest the firm’s financial performance relied on inadequate patient care and the redirection of taxpayer funds to executives and affiliates. The report includes serious claims that these systemic failures directly contributed to patient harm and deaths.

Shareholders who purchased Ensign securities during the period in question are encouraged to contact attorney Phillip Kim at Rosen Law to discuss potential class action participation. The firm, which specializes in shareholder derivative litigation, seeks to recover investor losses through a contingency fee arrangement, meaning participants face no out-of-pocket costs. Rosen Law has previously secured significant settlements, including a record-breaking outcome against a Chinese firm and over $438 million for investors in 2019 alone.